SCHEMBL586203

SCHEMBL586203

CC(=O)CC(=O)OC(C)=O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGAM O43451 2/20 0.60
GAA P10253 2/20 0.60
SI P14410 2/20 0.60
MGAM2 Q2M2H8 2/20 0.60
ALDH1A1 P00352 6/20 0.50
TSHR P16473 4/20 0.50
TDP1 Q9NUW8 2/20 0.42
HSD17B10 Q99714 3/20 0.41
HTT P42858 1/20 0.36
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.35
KDM6B O15054 1/20 0.35
KDM5C P41229 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
PHF8 Q9UPP1 1/20 0.35
KDM2A Q9Y2K7 1/20 0.35
TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15847228 1.00 MGAM (0.60) MGAMGAASIMGAM2ALDH1A1
SCHEMBL9280063 1.00 MGAM (0.60) MGAMGAASIMGAM2ALDH1A1
SCHEMBL28224529 1.00 MGAM (0.60) MGAMGAASIMGAM2ALDH1A1
SCHEMBL2532133 0.97 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1
SCHEMBL22472179 0.97 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1
SCHEMBL25283117 0.97 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1
SCHEMBL5481698 0.97 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1
SCHEMBL17994176 0.97 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1
SCHEMBL4990677 0.97 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1
SCHEMBL17105598 0.97 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11975023-B2 Methods for inhibiting anaerobic microorganisms LPOXY THERAPEUTICS, INC (US) 2024-05-07 US claimed
US-11944641-B2 Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy LPOXY THERAPEUTICS, INC. (US) 2024-04-02 US claimed
US-11883428-B2 Enteric aerobization therapy LPOXY THERAPEUTICS, INC. (US) 2024-01-30 US claimed
CN-112852301-B Photosensitive color-changing pencil paint and process for producing photosensitive color-changing pencil by using same 中国第一铅笔有限公司 2022-03-15 CN claimed
CN-111718484-B High-performance dynamic cross-linked polymer based on vinyl hydrazide bond and preparation method thereof 四川大学 2021-10-12 CN claimed
CN-108441028-B Photosensitive ink material and preparation method thereof 深圳市格莱特印刷材料有限公司 2021-06-15 CN claimed
CN-112844374-A Mn-Ce-Ti oxide aerogel denitration catalyst and preparation method and application thereof 上海应用技术大学 2021-05-28 CN claimed
CN-111718484-A High-performance dynamic cross-linked polymer based on vinyl hydrazide bond and preparation method thereof 四川大学 2020-09-29 CN claimed
CN-107163205-B A kind of unsaturated polyester (UP) performed polymer of ketone group containing and its preparation method and application 常州大学 2019-03-22 CN claimed
CN-108441028-A A kind of photosensitive ink material and preparation method thereof 深圳市格莱特印刷材料有限公司 2018-08-24 CN claimed
CN-101012291-A Encapsulated michael addition catalyst ROHM & HAAS (US) 2007-08-08 CN claimed
CN-1898330-A Multifunctional acrylate oligomers as pigment grinding vehicles for radiation-curable ink applications ASHLAND LICENSING & INTELLECTU (US) 2007-01-17 CN claimed
CN-1894291-A Radiation curable inks for offset and screen printing applications made from multifunctional acrylate oligomers ASHLAND LICENSING & INTELLECTU (US) 2007-01-10 CN claimed
CN-1267209-C Method for using Michael addition composite ROHM & HAAS (US) 2006-08-02 CN claimed
WO-2006002031-A1 SUSTAINED RELEASE DOSAGE FORMS ANDRX CORPORATION (US) 2006-01-05 WO claimed
US-20050276849-A1 Sustained release dosage forms ANDRX CORPORATION 2005-12-15 US claimed
CN-1708401-A Liquid uncrosslinked michael addition oligomers prepared in the presence of a catalyst having both an epoxy moiety and a quaternary salt ASHLAND INC (US) 2005-12-14 CN claimed
EP-1097216-A1 METABOLICALLY ENGINEERED MICROBIAL CELL WITH AN ALTERED METABOLITE PRODUCTION Nielsen, Jens (DK) 2001-05-09 EP claimed
WO-2000003020-A1 METABOLICALLY ENGINEERED MICROBIAL CELL WITH AN ALTERED METABOLITE PRODUCTION NIELSEN JENS (DK) 2000-01-20 WO claimed
US-5811121-A PH-sensitive coatings based on cellulose acetoacetate EASTMAN CHEMICAL COMPANY (US) 1998-09-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11975023-B2 Methods for inhibiting anaerobic microorganisms SI, MB, ALPI MGAM 62/4885GAA 436/4885SI 1/4885
US-11883428-B2 Enteric aerobization therapy SI, MB, LPO MGAM 18/4885GAA 434/4885SI 1/4885
US-11944641-B2 Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy MB, NOD2, SI MGAM 150/4885GAA 588/4885SI 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.